Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

EDITOR:
Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE PLANNERS:
Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Senior Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

INDIVIDUALS WHO PROVIDED CONTENT DEVELOPMENT AND/OR AUTHORSHIP ASSISTANCE:
William J. Gradishar, MD, Panel Chair, has disclosed that he has no relevant financial relationships.

Benjamin O. Anderson, MD, Panel Vice-Chair, has disclosed that he has no relevant financial relationships.

Sarah L. Blair, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Amy Cyr, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Anthony D. Elias, MD, Panel Member, has disclosed that he receives grant/research support from Eisai Inc., Medivation, Inc., Astellas US LLC, ZIOPHARM Oncology, Inc., ImClone Systems Incorporated, Genentech, Inc., Incyte Corporation, and Johnson & Johnson Services, Inc.; has equity interest/stock options in Pfizer Inc., Genentech, Inc., and Bristol-Myers Squibb Company; and is a scientific advisor for Genentech, Inc.

Andres Forero, MD, Panel Member, had disclosed that he receives grant/research support from Genentech/Roche, Novartis Pharmaceuticals Corporation, Daiichi Sankyo, Inc., Seattle Genetics, Inc., TRACON Pharmaceuticals, Inc., MedImmune, LLC, Incyte Corporation, Celgene Corporation, AbbVie Inc., GlaxoSmithKline plc, and Pfizer Inc.

Matthew Goetz, MD, Panel Member, has disclosed that he is a scientific advisor trial for Lilly Oncology.

Lori J. Goldstein, MD, Panel Member, has disclosed that she has no relevant financial relationships.

Clifford A. Hudis, MD, Panel Member, has disclosed that he receives consulting fees and honoraria from Eli Lilly and Company, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Roche Laboratories, Inc.; and serves as a scientific advisor for Pfizer Inc. and Roche Laboratories, Inc.

Steven J. Isakoff, MD, PhD, Panel Member, has disclosed that he receives grant/research support from AbbVie Inc., Genentech, Inc., and PharmaMar; and receives consulting fees from Merrimack Pharmaceuticals, Inc., AbbVie Inc., and Myriad Genetics, Inc.

Kilian E. Salerno, MD, Panel Member, has disclosed that he has no relevant financial relationships.

Karen Lisa Smith, MD, MPH, Panel Member, has disclosed that she has equity interest/stock options in AbbVie Inc., Abbott Laboratories, Express Scripts, and Hospira, Inc.

Hatem Soliman, MD, Panel Member, has disclosed that he receives consulting fees from Celgene Corporation.

George Somlo, MD, Panel Member, has disclosed that he receives grant/research support from Genentech, Inc., Agendia, and AstraZeneca Pharmaceuticals LP; is a scientific advisor for Pfizer Inc., Genentech, Inc., and Agendia; and is a member of a speakers’ bureau for Takeda.

Melinda Telli, MD, Panel Member, has disclosed that she receives other financial benefit from Vertex Pharmaceuticals Incorporated.

Dorothy A. Shead, MS, Director, Patient & Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.